This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
Roger Denton of Schlichter, Bogard & Denton, LLP reports that a recent lawsuit alleges that the blood thinning medication Xarelto® is linked to serious and life-threatening bleeding events.
St. Louis, MO (PRWEB) June 27, 2014
According to a recent lawsuit filed in the Philadelphia County Court of Common Pleas (Stuntebeck v. Janssen Research & Development LLC et al, Case No.140201754), the anticoagulant drug Xarelto® (rivaroxaban) is alleged to cause serious and uncontrolled internal bleeding that might be irreversible, that could result in life-threatening injuries and even death.
The anti-clotting medication Xarelto®, which is marketed by Johnson & Johnson in the United States and by Bayer outside the United States, was approved by the Food and Drug Administration (FDA) in July 2011 for use in patients who recently underwent hip or knee replacement surgery to reduce the risk of blood clots. According to a press release issued by the FDA, in November 2011 the FDA approved another indication of Xarelto® for patients with atrial fibrillation (AF) to reduce the risk of stroke. Then in 2012, according to a press release issued by the FDA, the FDA approved another indication of Xarelto® expanding its use for the general treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
We will fight for the rights of individuals who allege to have experienced serious and life-threatening injuries after using Xarelto®, says Roger Denton of Schlichter, Bogard & Denton, LLP. He adds, "The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have been injured after using Xarelto®."
About Schlichter, Bogard & Denton, LLP
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in national litigations involving dangerous pharmaceutical medications and unsafe medical devices, including but not limited to: In re: Pradaxa® (Dabigatran Etexilate) Products Liability (MDL 2385, Case No. 12-md-2385, S.D. Ill.), In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100, Case No. 09-md-2100, S.D. Ill.), In re: NuvaRing® Products Liability Litigation (MDL 1964, Case No. 08-md-1964, E.D. Mo.), In re: Gadolinium-Based Contrast Products Liability Litigation (MDL 1909, Case No. 08-gd-50000, N.D. Ohio), and In re: Ortho Evra® Products Liability Litigation (MDL 1742, Case No. 06-gd-40000, N.D. Ohio).
The Pharmaceuticals and Medical Litigation Department at Schlichter, Bogard & Denton aggressively represent clients who allege to have suffered injuries as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys at Schlichter, Bogard & Denton, LLP who represent such victims include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious and life-threatening injuries, or even death.
If you or a loved one has suffered serious injuries after using Xarelto®, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. Schlichter, Bogard & Denton, LLP is available to either handle these cases or work as co-counsel, so other attorneys with these types of cases are invited to contact an attorney at the firm to explore this opportunity.
The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/06/prweb11979477.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.